Gemcitabine in Bone Sarcoma Resistant to Doxorubicin-Based Chemotherapy

Subjects and Methods: Seven patients with progressive localized or metastatic chemo-resistant osteosarcoma were treated by gemcitabine.The protocol included gemcitabine 1000 mg/m2/w for 7 consecutive weeks, followed by 1 week rest. If no progression was observed,maintenance by gemcitabine 1000 mg/m2/w for 3 weeks every 28 days was given until failure was clinically or radiologically evident

Periosteal Ewing's Sarcoma: Report of Two New Cases and Review of the Literature

Background. The origin of Ewing's sarcoma in a periosteal location is rare and not clearly documented. Other malignant bone tumors appear to have a somewhat better prognosis when confined between periosteum and bone. Is it the same for periosteal Ewing's sarcoma

Cluster analysis and a hierarchical tree comparing mucosal microRNA expression alterations in ileal mucosa of different IBD subgroups and normal controls.

<p>Cluster analysis and a hierarchical tree comparing microRNA expression alterations in IBD subgroups: normal pouch (NP), chronic pouchitis (CP), Crohn’s-like disease of the pouch (CLDP), unoperated ulcerative colitis (UC), ileal Crohn’s disease (CD), and normal controls (NC). Each bar represents a single individual. The hierarchical tree is represented by black lines.</p

Inflammatory conditions induce increased miRNA expression in intestinal epithelial cells.

<p>(A) HCT-116 and (B) Caco2 cells after incubation with pro-inflammatory cytokines. Relative microRNA expression alterations were calculated for each tested microRNA (mir) after treatment with IL-1β, TNF-α, and INF-γ, compared to the expression level of the corresponding untreated cells. *P <0.05.</p

Overlap in altered microRNAs in the three pouch groups.

<p>The Venn diagram shows the overlap of microRNA alterations among the pouch groups (normal pouch [NP], chronic pouchitis [CP], and Crohn’s-like disease of the pouch [CLDP]). The numbers in parentheses represent the total number of alterations compared to NC in each group.</p

Demographics and clinical characteristics.

<p>Demographics and clinical characteristics.</p

Validation of miRNA alterations.

<p>Validation of 18 altered miRNAs obtained from ileal/pouch biopsies from an independent cohort of patients with normal pouch (NP), chronic pouchitis (CP) and Crohn’s-like disease of the pouch (CLDP), and normal controls (NC) using RT-PCR. The average levels of controls were designated as relative quantification (RQ) 1. *P <0.05, **P <0.01.</p